Sertraline and Tamoxifen: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Sertraline
No brand names on recordTamoxifen
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Tamoxifen is a bit like a package that your body has to open before it fully works. An enzyme called CYP2D6 opens it and turns it into its most active form, called endoxifen. Sertraline can slow that enzyme down, so in theory you might make less of the active form of tamoxifen.
The good news is reassuring: large studies of women taking both did not find worse breast cancer outcomes. There is also a small, theoretical concern that both drugs can affect your heart's rhythm. Please don't change anything on your own. Your care team can look at whether a different antidepressant fits you better, and they can keep an eye on things.
Mechanism: Tamoxifen is a prodrug requiring CYP2D6 to form its active metabolite endoxifen. Sertraline is a mild-to-moderate CYP2D6 inhibitor, so coadministration may reduce endoxifen exposure (reduced active effect). Additive QT prolongation is also possible.
- Direction: reduced active tamoxifen metabolite; additive QT risk
- Onset: delayed
- Evidence: theoretical; large retrospective studies show no significant impact of sertraline on breast cancer recurrence or mortality (unlike paroxetine)
- Management: Where feasible, prefer an antidepressant with little/no CYP2D6 inhibition. If combined, monitor QT/electrolytes per risk factors. Individualize decisions with the care team.
What happens
Reduced exposure of active tamoxifen metabolites and an increased risk of QT interval prolongation
Interaction Deep Dive
The combined use of sertraline and tamoxifen should be avoided, because it may raise the likelihood of QT prolongation and/or ventricular arrhythmias1. Giving sertraline together with tamoxifen may lower the plasma level of tamoxifen's principal active metabolite 2; nevertheless, large retrospective studies have shown that antidepressants, sertraline among them, have no meaningful effect on the risk of later breast cancer 4, and that using tamoxifen and sertraline together does not raise the risk of death from breast cancer, even though paroxetine was associated with such an increased risk. If antidepressant treatment must be given at the same time, options that have little or no CYP2D6 inhibition should be considered 3.
Why it happens (mechanism)
Inhibition of CYP2D6-mediated tamoxifen metabolism by sertraline; additive QT interval prolongation
How to manage this interaction
Keep taking both medicines as prescribed unless your prescriber tells you otherwise. This combination can be managed.
- Ask your oncologist and pharmacist whether an antidepressant with little or no effect on the CYP2D6 enzyme might be a better fit alongside tamoxifen.
- Your team may consider your personal heart-rhythm (QT) risk factors and monitor more closely if needed.
- Mention any history of heart rhythm problems, fainting, or other medicines that affect the heart.
- Reassuringly, real-world studies have not shown worse breast cancer outcomes with sertraline plus tamoxifen.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
4 reports — tap to read
a) A retrospective analysis of premenopausal women with stage I to III breast cancer from the Predictors of Breast Cancer Recurrence (ProBe CaRe) cohort (N=4493), employing Bayesian joint modeling, found that patients who used tamoxifen together with a CYP2D6 inhibitor, such as sertraline, for more than half of the planned tamoxifen-treatment duration experienced a greater rate of breast cancer recurrence than those who did not combine a CYP2D6 inhibitor with tamoxifen (HR, 1.24; 95% CI, 0.96 to 1.58). This relationship was more pronounced with strong CYP2D6 inhibitors (HR, 1.25; 95% CI, 0.88 to 1.73) than with weak CYP2D6 inhibitors (HR, 1.15; 95% CI, 0.57 to 1.53) 5.
b) In a retrospective review of 16,887 insured women who received tamoxifen for at least 6 months after a diagnosis of Stage 0 to II breast cancer, the risk of a subsequent breast cancer was not significantly raised with concurrent antidepressant use. The median length of tamoxifen use was 2.7 years. Among the 8089 patients prescribed antidepressants, the median number of days that antidepressant and tamoxifen use overlapped was 144 days. After a median follow-up of 6 years, 17.4% of all patients developed a subsequent breast cancer. Among the 10.6% of patients who received paroxetine, 25%, 50%, and 75% increases in overlapping use during the first year of tamoxifen corresponded to the largest increases in the risk of subsequent breast cancer (6%, 13%, and 20%, respectively), although these increases were not significant and lessened over time. Fluoxetine was the most frequently prescribed antidepressant (19.9%) and was linked to a 0%, 1%, and 3% nonsignificant increase in the risk of subsequent breast cancer for the corresponding 25%, 50%, and 75% increases in overlapping use during the first year of tamoxifen. Additional agents evaluated were grouped into categories of other SSRIs, tricyclics, and other types, which included venlafaxine, trazodone, bupropion, and tetracyclics 4.
c) Findings from a retrospective study showed that combining paroxetine with tamoxifen is associated with a heightened risk of death from breast cancer that correlates directly with how long the two are taken together, whereas the risk is not elevated with other SSRIs, such as sertraline. The study enrolled females aged at least 66 years who were newly started on tamoxifen for breast cancer and who also received a single SSRI antidepressant. Of the 2430 participants, 2025 began tamoxifen within 1 year of their breast cancer diagnosis, and the median length of tamoxifen therapy was 4 years. Paroxetine was the most commonly prescribed SSRI (n=630), while the others included sertraline (n=541), citalopram (n=467), venlafaxine (n=365), fluoxetine (n=253), and fluvoxamine (n=174). After a mean follow-up of 2.38 years, 374 women died of breast cancer. Absolute increases of 25%, 50%, and 75% in the proportion of tamoxifen time overlapping with paroxetine were linked to significant increases of 24%, 54%, and 91% in the risk of death from breast cancer, respectively. No other SSRI was associated with an increased risk of breast cancer mortality when given during tamoxifen therapy 3.
d) Combining paroxetine, a strong CYP2D6 inhibitor, with tamoxifen, which must be converted by CYP2D6 enzymes into the antiestrogenic metabolite (endoxifen), leads to markedly lower plasma levels of endoxifen. Eighty newly diagnosed breast cancer patients receiving tamoxifen 20 mg/day were genotyped for the common alleles of the CYP2D6, CYP2C9, CYP3A5, and sulfotransferase (SULT) 1A1 genes. Plasma concentrations of tamoxifen and endoxifen were measured after 1 and 4 months of tamoxifen therapy. Following 4 months of tamoxifen, plasma endoxifen levels were significantly lower in patients with a CYP2D6 homozygous variant genotype (20 nM) or a heterozygous genotype (43.1 nM) than in those with a homozygous wild-type genotype (78 nM). The mean plasma endoxifen level in subjects with a homozygous wild-type genotype who were taking CYP2D6 inhibitors was 58% lower than in those not taking such inhibitors (38.6 nM vs 91.4 nM). Concurrent use of venlafaxine, a weak CYP2D6 inhibitor, produced slightly lower plasma endoxifen concentrations, while paroxetine, a strong CYP2D6 inhibitor, caused substantial reductions in endoxifen concentrations, and sertraline produced intermediate reductions in endoxifen levels between those seen with venlafaxine and paroxetine 2.
Common questions
Can I take Sertraline and Tamoxifen together?
Sertraline may lower the active form of tamoxifen and both can affect heart rhythm, but real-world data have not shown worse breast cancer outcomes; ask your care team whether a different antidepressant is a better fit, and don't stop either drug on your own. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Sertraline and Tamoxifen interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "delayed". Effects tend to build up gradually over days to weeks.
How is the Sertraline and Tamoxifen interaction managed?
Keep taking both medicines as prescribed unless your prescriber tells you otherwise. This combination can be managed. Ask your oncologist and pharmacist whether an antidepressant with little or no effect on the CYP2D6 enzyme might be a better fit alongside tamoxifen. Your team may consider your personal heart-rhythm (QT) risk factors and monitor more closely if needed. Mention any history of heart… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Sertraline or Tamoxifen need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: ZOLOFT oral tablets, oral solution, sertraline hydrochloride oral tablets, oral solution. Viatris Specialty LLC (per FDA), Morgantown, WV, 2023. DailyMed
- Jin Y, Desta Z, Stearns V, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97(1):30-39. PubMed
- Kelly CM, Juurlink DN, Gomes T, et al: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340:c693. PubMed
- Haque R, Shi J, Schottinger JE, et al: Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 2016; 108(3):djv337-. PubMed
- Woolpert KM, Cronin-Fenton DP, Damkier P, et al: Drug interactions with tamoxifen and treatment effectiveness in premenopausal breast cancer patients: a Bayesian joint modeling approach. Pharmacoepidemiol Drug Saf 2025; 34(5):e70157-. DOI
Keep reading about Sertraline
Keep reading about Tamoxifen
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist